Breakthrough in Pancreatic Cancer Treatment: STING Signaling Relay Uncovered

Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest cancers, has long defied effective treatments due to its aggressive nature and immunosuppressive tumor microenvironment (TME). A groundbreaking study from China's State Key Laboratory of Oncology in South China at Sun Yat-sen University Cancer Center (SYSUCC) reveals how a 'STING signaling relay' from tumor cells to macrophages boosts the power of combination chemotherapy. Published on March 4, 2026, in the Journal of Biomedical Science, this research introduces the AGP regimen—gemcitabine plus nab-paclitaxel (AG) augmented with cisplatin—and explains its superior efficacy through activation of the cGAS-STING pathway.

The findings not only highlight a novel mechanism enhancing antitumor immunity but also position STING expression as a potential biomarker for better prognosis in PDAC patients. This discovery could transform how we approach immunotherapy in 'cold' tumors like PDAC, where immune cells struggle to infiltrate and attack.

The Persistent Challenge of Pancreatic Cancer

PDAC claims lives rapidly, with a mere 13% five-year overall survival (OS) rate, and projections suggest it will soon rank as the second leading cause of cancer deaths by 2030. At diagnosis, 80% of cases are advanced, ruling out surgery. Standard chemotherapies like FOLFIRINOX or AG offer modest OS gains—mere months—but resistance, dense stroma blocking drugs, and an immunosuppressive TME rich in regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and M2-polarized tumor-associated macrophages (TAMs) undermine progress.

The TME in PDAC is notoriously 'cold,' lacking effector T cells like CD8+ cytotoxic T lymphocytes that destroy tumors. Reprogramming this environment to ignite innate and adaptive immunity is crucial, and the cGAS-STING pathway—cyclic GMP-AMP synthase (cGAS) sensing cytosolic double-stranded DNA (dsDNA) to activate stimulator of interferon genes (STING)—emerges as a pivotal player. STING triggers type I interferons (IFNs) and chemokines, rallying immune forces against cancer.

Introducing the AGP Regimen: A Simple Addition with Profound Impact

The AG regimen—gemcitabine (a nucleoside analog inhibiting DNA synthesis) and nab-paclitaxel (albumin-bound paclitaxel disrupting microtubules)—is first-line for metastatic PDAC. Researchers added low-dose cisplatin, a platinum-based DNA crosslinker, creating AGP. In mouse models, dosing was gemcitabine (50 mg/kg), nab-paclitaxel (5 mg/kg), and cisplatin (5 mg/kg) intraperitoneally twice weekly for two weeks.

• Cisplatin uniquely induces DNA damage without excessive toxicity.
• Nab-paclitaxel enhances phagocytosis by upregulating macrophage receptors like SIRPα, Mertk, and Mrc1.
• Gemcitabine sustains immune activation.

This trio synergizes, far surpassing AG alone in preclinical and early clinical data.

Decoding the STING Signaling Relay: Step-by-Step Mechanism

The cGAS-STING pathway detects cytosolic DNA from pathogens or damage, producing second messenger 2'3'-cGAMP, which binds STING on the endoplasmic reticulum. STING oligomerizes, traffics to Golgi, recruits TBK1 to phosphorylate IRF3, inducing type I IFNs and proinflammatory cytokines.

In this relay:

1. Cisplatin causes DNA double-strand breaks and mitochondrial DNA (mtDNA) release in PDAC cells, marked by γ-H2AX foci and cytosolic dsDNA.
2. Tumor-intrinsic cGAS binds dsDNA, generates cGAMP, activates STING (p-STING upregulation), TBK1/IRF3 phosphorylation, boosting IFN-α/β, chemokines (CCL5, CXCL9/10), MHC-I (β2M, TAP1, ERAP1), and PD-L1.
3. This recruits CD8+ T cells, reduces exhaustion (down PD-1/Tim-3/CD39).
4. Tumor-derived damage-associated molecular patterns (DAMPs, e.g., mtDNA) are phagocytosed by TAMs (enhanced by nab-paclitaxel).
5. In TAMs, phagocytosed dsDNA activates cGAS-STING, polarizing to antitumor M1 phenotype (iNOS+, CD80+, reduced CD206), secreting cytokines without apoptosis.
6. Result: Remodeled TME with more CD8+ T cells, B cells, M1 TAMs; fewer Tregs, M-MDSCs.

Validation via CRISPR Sting KO in tumor cells/macrophages (LysM-Cre) abolished benefits.

For deeper insights, explore research positions at leading oncology centers via our research jobs page.

Photo by National Institute of Allergy and Infectious Diseases on Unsplash

Robust Evidence from Advanced Mouse Models

Using KPC-derived lines (KPC-1199 on C57BL/6), subcutaneous and orthotopic models showed AGP sharply curtailed tumor growth, increased necrosis, and prolonged survival versus AG or controls. Bioluminescence imaging confirmed orthotopic suppression.

Immune profiling via CyTOF (42 markers), flow cytometry, multiplex IF, and RNA-seq revealed:

• Increased CD8+ T cells (naïve/memory), B cells, M1 TAMs (CD80+, iNOS+).
• Decreased M-MDSCs, Tregs.
• T cell activation (higher IFN-γ, Granzyme B).
• Spatial analysis: Closer CD8+-TAM proximity post-AGP.

Co-culture assays confirmed tumor-macrophage crosstalk drives T cell priming (LacZ reporter for OVA-specific T cells). Check higher ed jobs in immunology for hands-on opportunities.

Promising Clinical Data from SYSUCC Cohort

Retrospective analysis of 108 advanced PDAC patients (2019–2023) at SYSUCC: AGP (n=10) showed superior progression-free survival (PFS: HR=0.44 unmatched, 0.25 matched, p=0.013) versus AG (n=98/20 matched). Objective response rate 40% (4 partial responses, 6 stable), with 90% shrinkage in responders. OS trends favored AGP but not significant (small n). Adverse events similar, mild thrombocytopenia increase.

In 56-patient IHC cohort, high STING expression linked to more CD8+ T cells, M1 macrophages (CD86+), fewer M2 (CD206+), and independently predicted OS (HR=0.25, p<0.001). TCGA validation confirmed.

Transforming Cancer Immunotherapy Landscape

This relay leverages chemotherapy to activate STING without synthetic agonists, sidestepping toxicity/delivery issues in trials. PD-L1 upregulation suggests synergy with checkpoint inhibitors. STING as biomarker could stratify patients for personalized therapy.

China leads: SYSUCC's work builds on national immunotherapy push, with STING trials ongoing (e.g., surufatinib combos).

Sun Yat-sen University Cancer Center: Hub of Oncology Innovation

SYSUCC, home to the State Key Laboratory of Oncology in South China, pioneered this via interdisciplinary teams. Lead author Honglu Ding (Pancreatobiliary Surgery) and colleagues from Guangzhou National Lab exemplify China's oncology prowess, publishing in top journals amid rising global impact.

Prospective trials needed, but AGP offers immediate hope. Explore faculty roles at professor jobs or higher ed faculty positions.

Photo by Michał Lis on Unsplash

Future Outlook: From Bench to Bedside

Limitations: Retrospective design, small AGP cohort. Next: Phase II/III trials, single-cell/spatial omics for DAMPs, combos with PD-1/PD-L1 inhibitors. China's STING ecosystem—nanomaterials, agonists—positions it forefront.

• Prospective AGP validation.
• STING agonists + chemo.
• Biomarker-driven trials.
• Broader solid tumors.

Discover career advice at higher ed career advice. Share insights in comments.